<DOC>
	<DOCNO>NCT00232934</DOCNO>
	<brief_summary>The purpose study determine whether association Thalidomide Melphalan Prednisone effective treatment newly diagnose elderly multiple myeloma .</brief_summary>
	<brief_title>Melphalan , Prednisone Thalidomide Versus Melphalan Prednisone Elderly Myeloma Patients</brief_title>
	<detailed_description>Intermittent course Melphalan Prednisone ( MP ) first line therapy multiple myeloma , many year . Advances systemic supportive therapy increase remission rate overall survival , multiple myeloma still remain incurable haematological malignancy . Several preliminary study demonstrate efficacy thalidomide refractory relapse multiple myeloma overall response rate 30 60 % . Due activity , Thalidomide evaluate association MP randomize study newly diagnose myeloma patient eligible high-dose chemotherapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>untreated myeloma patient age &gt; 65 year age younger exclude transplant procedure Durie &amp; Salmon stage II III myeloma measurable disease . Patients agree use contraception cancer psychiatric disease grade 2 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Elderly patient</keyword>
</DOC>